Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 60 of 279 for:    Best Disease

Bergen Psychosis Project 2 - The Best Intro Study (BP2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01446328
Recruitment Status : Completed
First Posted : October 5, 2011
Last Update Posted : January 30, 2018
Sponsor:
Collaborator:
Helse Vest
Information provided by (Responsible Party):
Haukeland University Hospital

Brief Summary:
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months. The study is independent of the pharmaceutical industry, and in accordance with a pragmatic design a clinically relevant sample will be included with as few exclusion criteria as possible. The patients will be assessed repeatedly with regards to symptoms, side effects, and cognitive functioning, as well as laboratory parameters. The study hypothesis is that clinically meaningful differences among the drugs will be disclosed in a pragmatic design.

Condition or disease Intervention/treatment Phase
Schizophrenia Psychotic Disorders Drug: Amisulpride Drug: Aripiprazole Drug: Olanzapine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 151 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study
Study Start Date : October 2011
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Amisulpride Drug: Amisulpride
Tablets, dose range 50-1200 mg/ day
Other Name: Solian

Active Comparator: Aripiprazole Drug: Aripiprazole
Tablets, dose range 5-30 mg/ day
Other Name: Abilify

Active Comparator: Olanzapine Drug: Olanzapine
Tablets, dose range 2.5-20 mg/ day
Other Name: Zyprexa




Primary Outcome Measures :
  1. Change of the Positive and Negative Syndrome Scale total score [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A:The observational cohort

  • Patients 16 years old or older
  • Active psychosis as determined by a score of 4 or more on one or more of the items Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).
  • Or ICD-10 diagnosis corresponding to psychotic disorders or other mental disorders with psychotic features (F10-F19: .5 (psychotic disorder); F20-F29, F30.2, F31.2, F31.5, F32.3, F33.3). From which eligible patients are recruited to the B:The pragmatic, randomized, controlled trial (The Best Intro Study)
  • Patients 18 years and older
  • Schizophrenia spectrum and delusional disorder
  • Symptoms of psychosis as determined by a score of 4 or more on one or more of the items Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).

Exclusion Criteria:

  • Inability to understand spoken Norwegian.
  • Patients with organic psychosis due to limbic encephalitis detected by antibodies in serum obtains at inclusion (such as NMDAR, VGKC and paraneoplastic antibodies performed at the Neuroimmunology Laboratory, Department of Neurology, Haukeland University Hospital) Pregnant or breast feeding women.
  • Aripiprazole: Hypersensitivity to the active substance or to any of the excipients
  • Amisulpride: Hypersensitivity to the active ingredient or to other ingredients of the medicinal product; concomitant prolactin-dependent tumours e.g. pituitary gland prolactinomas and breast cancer; phaeochromocytoma; lactation, combination with the following medications which could induce torsade de pointes: Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide. Class III antiarrhythmic agents such as amiodarone, sotalol. Other medications such as bepridil, cisapride, sultopride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin. Combinations with levodopa.
  • Olanzapine: Hypersensitivity to the active substance or to any of the excipients. Patients with known risk of narrow-angle glaucoma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01446328


Locations
Layout table for location information
Austria
Medizinische Universität Innsbruck
Innsbruck, Austria, 6020
Norway
Haukeland University Hospital
Bergen, Norway, 5223
Stavanger University Hospital
Stavanger, Norway
St. Olavs Hospital
Trondheim, Norway
Sponsors and Collaborators
Haukeland University Hospital
Helse Vest
Investigators
Layout table for investigator information
Principal Investigator: Erik Johnsen, M.D., Ph.D. Haukeland University Hospital

Layout table for additonal information
Responsible Party: Haukeland University Hospital
ClinicalTrials.gov Identifier: NCT01446328     History of Changes
Other Study ID Numbers: 2010/3387
11/01070 ( Other Identifier: The Norwegian Medicines Agency )
2010-022307-22 ( EudraCT Number )
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: January 30, 2018
Last Verified: January 2018

Keywords provided by Haukeland University Hospital:
Antipsychotic Drugs
Randomized Controlled Trial
Treatment Effectiveness
Translational Research

Additional relevant MeSH terms:
Layout table for MeSH terms
Psychotic Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Schizophrenia
Aripiprazole
Amisulpride
Olanzapine
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors